Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study . Study Questions: What are the cardiovascular (CV) outcomes in patients initiated on sodium-glucose cotransporter-2 inhibitors (SGLT-2i) versus other glucose-lowering drugs (oGLD) across six countries in the Asia Pacific, the Middle East, and North America? Methods: The CVD-REAL 2 study investigators identified new users of SGLT-2i and oGLD via claims, and national registries in South Korea, Japan, Singapore, Israel, Australia, and Canada.
Propensity scores for SGLT2i initiation were developed in each country, with 1:1 matching. Hazard ratios (HRs) for death, hospitalization for heart failure (HHF), death or HHF, myocardial infarction (MI), and stroke were assessed by country and pooled using weighted meta-analysis. Results: After propensity-matching, there were 235,064…
